Latest News for: clofazimine

Edit

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of ...

Nasdaq Globe Newswire 06 May 2024
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE ... .
Edit

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of ...

The Associated Press 23 Jan 2023
“We are encouraged by the preclinical and Phase 1 data, and how inhaled clofazimine may finally resolve these issues, and most importantly, provide patients with a potentially improved NTM therapy.”.
Edit

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential ...

Eagle-Tribune 23 Jan 2023
“We are encouraged by the preclinical and Phase 1 data, and how inhaled clofazimine may finally resolve these issues, and most importantly, provide patients with a potentially improved NTM therapy.”.
Edit

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

Nasdaq Globe Newswire 06 Sep 2022
... 1 study of clofazimine inhalation suspension (MNKD 101) and is planning discussions with the U.S.
Edit

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine (MannKind Corporation)

Public Technologies 06 Sep 2022
Clofazimine is being developed as an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease ... seeing with inhaled clofazimine and the future potential to help patients.".
  • 1

Most Viewed

×